Kisqali

Kisqali, also known by its generic name ribociclib, is a prescription medication used to treat certain types of breast cancer. It is classified as a cyclin-dependent kinase (CDK) inhibitor, specifically targeting CDK4 and CDK6. These enzymes play a role in cell growth and division, and in some breast cancers, they are overactive, leading to uncontrolled tumor growth.

Kisqali is typically prescribed in combination with endocrine therapy, such as an aromatase inhibitor or fulvestrant, for postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is administered orally in tablet form. The medication works by blocking the activity of CDK4 and CDK6, thereby slowing down or stopping the growth of cancer cells.

The effectiveness of Kisqali has been demonstrated in clinical trials, showing improvements in progression-free survival and overall survival when used in combination with endocrine therapy. Common side effects associated with Kisqali include neutropenia (low white blood cell count), nausea, fatigue, diarrhea, hair loss, and elevated liver enzymes. Regular monitoring of blood counts and liver function is necessary during treatment. Kisqali is a significant therapeutic option for a specific subset of breast cancer patients.